Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

ERA-63

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
ERA-63
Clinical data
Other names3-Methylene-7α-methylethinylestradiol; 3-Methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol[1]
Identifiers
  • (7R,8R,9S,13S,14S,17R)-17-Ethynyl-7,13-dimethyl-3-methylidene-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
CAS Number
PubChemCID
ChemSpider
Chemical and physical data
FormulaC22H30O
Molar mass310.481 g·mol−1
3D model (JSmol)
  • C[C@@H]1CC2=C(CCC(=C)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
  • InChI=1S/C22H30O/c1-5-22(23)11-9-19-20-15(3)13-16-12-14(2)6-7-17(16)18(20)8-10-21(19,22)4/h1,15,18-20,23H,2,6-13H2,3-4H3/t15-,18-,19+,20-,21+,22+/m1/s1
  • Key:ITYURVXIFIQGDB-LADQHVHVSA-N

ERA-63, also known asORG-37663, as well as3-methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol, is asynthetic,steroidalestrogen and aselectiveagonist of theERα that was under development for the treatment ofrheumatoid arthritis but was never marketed.[2][1] The drug produced estrogenic effects but failed to showeffectiveness for rheumatoid arthritis in aphase IIaclinical study.[3][4] A large clinical trial also found thatprinaberel (ERB-041), a selectiveERβ agonist, was ineffective in the treatment of rheumatoid arthritis in spite of activity inpreclinicalmodels.[4]

See also

[edit]

References

[edit]
  1. ^abJanssen GB, Penninks AH, Knippels LM, van Zijverden M, Spanhaak S (2008). "The evaluation of the immunomodulating properties of ERA-63 a pharmaceutical with estrogenic activity".Toxicol. Lett.180 (3):196–201.doi:10.1016/j.toxlet.2008.06.857.PMID 18602456.
  2. ^Dulos J, Hofstra CL, Joosten L, Veening-Griffioen DH, Lucassen MA, Doorn CM, Graaf JH, Miltenburg A, Dijcks FA, Ederveen TH, Boots AM (2006). "A selective estrogen receptor alpha agonist (Org 37663) suppresses inflammation and arthritis in mouse models".Annals of the Rheumatic Diseases.65: 128.
  3. ^van Vollenhoven RF, Houbiers JG, Buttgereit F, In 't Hout J, Boers M, Leij S, Kvien TK, Dijkmans BA, Szczepański L, Szombati I, Sierakowski S, Miltenburg AM (2010). "The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine".Arthritis Rheum.62 (2):351–8.doi:10.1002/art.27196.PMID 20112368.
  4. ^abCutolo M (2010)."Selective estrogen receptor agonism lacks clinical benefit in rheumatoid arthritis: comment on the article by van Vollenhoven et al".Arthritis Rheum.62 (12):3832–3.doi:10.1002/art.27722.PMID 21120998.
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown


This article about anestrane is astub. You can help Wikipedia byexpanding it.

Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ERA-63&oldid=1308581605"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp